Market Sentiment for VRTX

Live Market Sentiment

Strong Positive (0.8838)

(Latest daily score)

Predicted Return

50.77%

7-day sentiment average

Advisory Opinion

Strong Buy

Derived from sentiment trend

News Items (period)

1,597

The table below gives each of the most recent headlines of the stock and the negative, neutral, positive aggregated sentiment score.

Date	Headline	Source	Sentiment
2026-04-02	Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note	Zacks	Strong Negative (-0.7792)
2026-04-02	1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds	StockStory	Strong Negative (-0.7299)
2026-04-01	Vertex Expands Cystic Fibrosis Reach As Kidney Drug Nears FDA Decision	Simply Wall St.	Strong Positive (0.8337)
2026-04-01	Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States	Business Wire	Strong Positive (0.9308)
2026-03-30	1 Cash-Producing Stock with Promising Prospects and 2 We Turn Down	StockStory	Positive (0.3444)
2026-03-28	What are U.S. companies doing with cash?	Investing.com	Negative (-0.1221)
2026-03-28	Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550	Insider Monkey	Strong Positive (0.7702)
2026-03-27	Jim Cramer on Corteva, Inc.: “I Would Continue to Own the Stock”	Insider Monkey	Neutral (0.0655)
2026-03-27	Regeneron (REGN) and Sanofi Announce Dupixent Approval in Japan to Treat Bullous Pemphigoid	Insider Monkey	Strong Positive (0.7962)
2026-03-27	2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds	StockStory	Positive (0.2667)